Search Within

GDMT, Medicine

  1. "Early Drug Development Service"
Formats
  1. Journal Article (42)
  2. Meeting Abstract (29)
  3. Book Section (1)
Groups
  1. Department of Medicine (72)
  2. Early Drug Development Service (72)
  3. Gynecologic Medicine Service (72)
  4. Gynecology Disease Management Team (72)
  5. Solid Tumor Oncology Division (72)
  6. Epidemiology and Biostatistics (35)

More Groups

People
  1. David Hyman (61)
  2. Carol Aghajanian (36)
  3. Rachel Grisham (33)
  4. Vicky Makker (25)
  5. Martee Hensley (24)
  6. Alexia Iasonos (23)

More People

Years
  1. 2025 (1)
  2. 2024 (4)
  3. 2023 (1)
  4. 2022 (3)
  5. 2021 (2)
  6. 2020 (10)

More Years

Publications
  1. Journal of Clinical Oncology (21)
  2. Gynecologic Oncology (10)
  3. Clinical Cancer Research (8)
  4. JCO Precision Oncology (5)
  5. Annals of Oncology (3)
  6. Cancer (3)

More Publications

Publishers
  1. American Society of Clinical Oncology (26)
  2. Elsevier Inc. (13)
  3. American Association for Cancer Research (12)
  4. Lippincott Williams & Wilkins (5)
  5. Oxford University Press (3)
  6. Springer (3)

More Publishers

Results (72)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Genomic profiling aids classification of diagnostically challenging uterine mesenchymal tumors with myomelanocytic differentiation
    Journal Article

    Selenica, P.; Conlon, N.; Gonzalez, C.; Frosina, D.; Jungbluth, A. A.; Beets-Tan, R. G. H.; Rao, M. K.; Zhang, Y.; Benayed, R.; Ladanyi, M.; more...
    American Journal of Surgical Pathology (2021)

    Fulltext@MSK | Save
  • Basket study of the oral progesterone antagonist onapristone ER in women with progesterone receptor positive (PR plus ) recurrent granulosa cell tumor (GCT), low-grade serous ovarian cancer (LGSOC), or endometrioid endometrial cancer (EEC)
    Meeting Abstract

    Grisham, R. N.; Li, K.; Iasonos, A.; Girshman, J.; Cadoo, K. A.; Kyi, C.; Makker, V.; Cohen, S. M.; O'Cearbhaill, R. E.; Sabbatini, P.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Immune and genomic profiling of small cell carcinomas of the ovary hypercalcemic type
    Meeting Abstract

    Dessources, K.; Holland, A.; Liu, J. D.; Lee, S. S.; Selenica, P.; Wu, M.; Stylianou, A.; Reis-Filho, J.; Hyman, D. M.; Hollmann, T. J.; more...
    Gynecologic Oncology (2020)

    Fulltext@MSK | Save
  • Single-arm, open-label, phase II study of LY3023414 for the treatment of recurrent or persistent endometrial cancer
    Meeting Abstract

    Rubinstein, M. M.; Hyman, D.; Caird, I.; O'Cearbhaill, R.; Grisham, R.; Tew, W.; Hensley, M.; Sabbatini, P.; Aghajanian, C.; Iasonos, A.; more...
    Molecular Cancer Research (2020)

    Fulltext@MSK | Save
  • The impact of poly ADP ribose polymerase (PARP) inhibitors on clonal hematopoiesis
    Meeting Abstract

    Bolton, K. L.; Moukarzel, L. A.; Ptashkin, R.; Gao, T.; Patel, M.; Caltabellotta, N.; Braunstein, L. Z.; Aghajanian, C.; Hyman, D. M.; Berger, M. F.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial
    Journal Article

    Oaknin, A.; Friedman, C. F.; Roman, L. D.; D'Souza, A.; Brana, I.; Bidard, F. C.; Goldman, J.; Alvarez, E. A.; Boni, V.; ElNaggar, A. C.; more...
    Gynecologic Oncology (2020)

    Fulltext@MSK | Save
  • Characterization of on-target adverse events caused by TRK inhibitor therapy
    Journal Article

    Liu, D.; Flory, J.; Lin, A.; Offin, M.; Falcon, C. J.; Murciano-Goroff, Y. R.; Rosen, E.; Guo, R.; Basu, E.; Li, B. T.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Genomic landscape of uterine sarcomas defined through prospective clinical sequencing
    Journal Article

    Hensley, M. L.; Chavan, S. S.; Solit, D. B.; Murali, R.; Soslow, R.; Chiang, S.; Jungbluth, A. A.; Bandlamudi, C.; Srinivasan, P.; Tap, W. D.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers
    Journal Article

    Li, B. T.; Michelini, F.; Misale, S.; Cocco, E.; Baldino, L.; Cai, Y.; Shifman, S.; Tu, H. Y.; Myers, M. L.; Xu, C.; more...
    Cancer Discovery (2020)

    Fulltext@MSK | Save
  • Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway
    Journal Article

    Rubinstein, M. M.; Hyman, D. M.; Caird, I.; Won, H.; Soldan, K.; Seier, K.; Iasonos, A.; Tew, W. P.; O’Cearbhaill, R. E.; Grisham, R. N.; more...
    Cancer (2020)

    Fulltext@MSK | Save